{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05156060",
            "orgStudyIdInfo": {
                "id": "VICC HNP 2173"
            },
            "organization": {
                "fullName": "Vanderbilt-Ingram Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer",
            "officialTitle": "Phase I/II Trial of Gabapentin Plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "gabapentin-ketamine-for-prevention-treatment-of-acute-chronic-pain-in-locally-advanced-head-and-neck-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-30",
            "studyFirstSubmitQcDate": "2021-11-30",
            "studyFirstPostDateStruct": {
                "date": "2021-12-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Natalie Lockney",
                "investigatorTitle": "Sponsor Investigator",
                "investigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
            },
            "leadSponsor": {
                "name": "Natalie Lockney",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.",
            "detailedDescription": "Objectives:\n\n* To establish the maximum tolerated dose of ketamine in combination with gabapentin up to a maximum planned dose of 40 mg three times a day.\n* To evaluate feasibility and tolerability\n\nExploratory:\n\n- To assess pain, symptom burden, functionality, and quality of life"
        },
        "conditionsModule": {
            "conditions": [
                "Head and Neck Cancer",
                "Locally Advanced Head and Neck Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 44,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Gabapentin plus Ketamine",
                    "type": "EXPERIMENTAL",
                    "description": "Gabapentin and Ketamine will be taken 3 times per day.",
                    "interventionNames": [
                        "Drug: Gabapentin",
                        "Drug: Ketamine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Gabapentin",
                    "description": "Taken by mouth 3 times per day",
                    "armGroupLabels": [
                        "Gabapentin plus Ketamine"
                    ],
                    "otherNames": [
                        "Neurontin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ketamine",
                    "description": "Administered intranasally 3 times per day",
                    "armGroupLabels": [
                        "Gabapentin plus Ketamine"
                    ],
                    "otherNames": [
                        "Ketalar"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Establish the maximum tolerated dose of ketamine in combination with gabapentin (per Common Terminology Criteria for Adverse Events Criteria 4.0)",
                    "description": "Up to a maximum planned dose of 40 mg three times a day",
                    "timeFrame": "Approximately 28 days (Phase I)"
                },
                {
                    "measure": "Count of participants with adverse events (Common Terminology Criteria for Adverse Events Criteria 4.0)",
                    "description": "Number of Participants With Grade 3 or 4 Adverse Events",
                    "timeFrame": "Up to 30 post-treatment (Phase II)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven cancer of the head and neck cancer\n* Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)\n* Planned primary or adjuvant radiation or chemoradiation therapy\n* Willing and able to provide informed consent\n* ECOG PS 0-2\n* Age \u2265 21 years\n* English speaking\n\nExclusion Criteria:\n\n* Currently on gabapentin or ketamine\n* Prior non-tolerance of gabapentin or ketamine\n* Unable to administer ketamine intranasally due to anatomical restrictions\n* History of seizure disorder\n* History of schizophrenia\n* History of increased intracranial pressure\n* Glomerular filtration rate \\<30 mL/min/1.73 m2",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vanderbilt-Ingram Service for Timely Access",
                    "role": "CONTACT",
                    "phone": "800-811-8480",
                    "email": "cip@vumc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Natalie Lockney, MD",
                    "affiliation": "Vanderbilt-Ingram Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Vanderbilt-Ingram Cancer Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vanderbilt-Ingram Service for Timely Access",
                            "role": "CONTACT",
                            "phone": "800-811-8480",
                            "email": "cip@vumc.org"
                        },
                        {
                            "name": "Natalie Lockney, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2021-08-22",
                    "uploadDate": "2021-11-08T09:56",
                    "filename": "ICF_000.pdf",
                    "size": 1440499
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000059350",
                    "term": "Chronic Pain"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M29442",
                    "name": "Chronic Pain",
                    "asFound": "Chronic Pain",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "asFound": "Head and Neck Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007649",
                    "term": "Ketamine"
                },
                {
                    "id": "D000077206",
                    "term": "Gabapentin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000778",
                    "term": "Anesthetics, Dissociative"
                },
                {
                    "id": "D000018686",
                    "term": "Anesthetics, Intravenous"
                },
                {
                    "id": "D000018681",
                    "term": "Anesthetics, General"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000018691",
                    "term": "Excitatory Amino Acid Antagonists"
                },
                {
                    "id": "D000018683",
                    "term": "Excitatory Amino Acid Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                },
                {
                    "id": "D000014151",
                    "term": "Anti-Anxiety Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018692",
                    "term": "Antimanic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10674",
                    "name": "Ketamine",
                    "asFound": "Nerve",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1694",
                    "name": "Gabapentin",
                    "asFound": "Guidance",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M4108",
                    "name": "Anesthetics, Dissociative",
                    "relevance": "LOW"
                },
                {
                    "id": "M20766",
                    "name": "Anesthetics, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M20761",
                    "name": "Anesthetics, General",
                    "relevance": "LOW"
                },
                {
                    "id": "M20771",
                    "name": "Excitatory Amino Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "relevance": "LOW"
                },
                {
                    "id": "M16905",
                    "name": "Anti-Anxiety Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                }
            ]
        }
    },
    "hasResults": false
}